Dji136

Preclinical

Dji136 is one of 8 therapeutic programs targeting Extensive Stage Small Cell Lung Cancer (ES-SCLC). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting

Extensive Stage Small Cell Lung Cancer (ES-SCLC)Preclinical

Recruiting

Competition

Competitive Landscape

8 competitors in Extensive Stage Small Cell Lung Cancer (ES-SCLC)

#DrugCompanyPhaseTrials

Zepzelca

Jazz Pharmaceuticals

Phase 3

1 2

TRODELVY

Gilead

Phase 3

1 3

Caitlyn

Bristol-Myers Squibb

Phase 3

1 4

Hycamtin

MMeitheal

Phase 3

1 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 6

Vepesid

AAvyxa

Phase 2

1 7

Tafolecimab

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 8

Dji136

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

PreclinicalRecruiting

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07564401

Clinical

Trials by Indication[1]

Extensive Stage Small Cell Lung Cancer (ES-SCLC)1 trial

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

Recruiting· Novartis logo

Novartis·Preclinical·NCT07564401·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dji136. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dji136. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Novartis

Dji136

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Extensive Stage Small Cell Lung Cancer (ES-SCLC)1 trial

References

Drug Info

Quick Facts

Related News